The confocal scanning laser ophthalmoscopy ancillary study to the ocular hypertension treatment study: study design and baseline factors☆
To access this article, please choose from the options below
☆ This study was supported by Grants EY11158, EY09341, and EY09307 from the National Eye Institute and the National Center of Minority Health and Health Disparities, National Institutes of Health, Bethesda, Maryland; Merck Research Laboratories, White House Station; and by an unrestricted grant from Research to Prevent Blindness, New York, New York. The authors have received support from the following companies: R.N.Weinreb: consultant or honoraria from Alcon and Novartis; consultant or honoraria and grant support or patent received/pending from Allergan Therapeutics, Heidelberg Engineering, Humphrey Instruments, Merck Research Laboratories, and Pharmacia/Upjohn; owns stock in Merck. J. M. Liebmann: consultant or honoraria from Allergan Therapeutics, Heidelberg Engineering, Novartis, and Pharmacia/Upjohn. J. D. Brandt: consultant or honoraria from Allergan, Merck, and Pharmacia/Upjohn. G. A. Cioffi: consultant or honoraria from Merck, Alcon Laboratories; consultant or honoraria and grant support/patent from Allergan, Ciba Vision, Heidelberg Engineering, Humphrey Instruments, Novartis, and Pharmacia/Upjohn. A. L. Coleman: grant support from Alcon Laboratories, consultant or honoraria from Allergan Therapeutics and Pharmacia/Upjohn. J. R. Piltz-Seymour: consultant or honoraria from Alcon, Allergan, Merck, and Pharmacia/Upjohn. M. A. Kass: consultant or honoraria from Merck and Pharmacia/Upjohn. L. M. Zangwill: research support (equipment) from Heidelberg Engineering, Laser Diagnostic Technologies, and Carl Zeiss Meditec.
PII: S0002-9394(03)00969-3
doi:10.1016/j.ajo.2003.08.031
© 2003 Elsevier Inc. All rights reserved.
